Carla A. Frederick MD

Research Expertise:

• Cystic Fibrosis: Director of Adult Cystic Fibrosis Center Co-Principal Investigator of Center for Therapeutic Drug Network at the Women & Children‘s Hospital of Buffalo
• New therapeutics in cystic fibrosis: Clinical care, clinical research, and translational research related to cystic fibrosis

Grants and Sponsored Research:

• August 2014–July 2018
  Success with Therapies Research Consortium
  Cystic Fibrosis Foundation
  Role: Principal Investigator
  $108,000
• January 2013–May 2015
  AquADEKs-2 trial: a study of the effects of an antioxidant-enriched multivitamin supplement on inflammation and oxidative stress in CF.
  Cystic Fibrosis Foundation
  Role: Co-Investigator
  
• January 2013–July 2014
  A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor Monotherapy and in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F50
  Vertex Pharmaceuticals, Inc.
  Role: Principal Investigator
  
• January 2013–January 2014
  A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa
  Gilead
  Role: Principal Investigator
  
• January 2010–January 2013
  iCARE: I Change Expectations and Raise Adherence
  Cystic Fibrosis Foundation/Genentech, Inc./Novartis Pharmaceuticals Corporation
  Role: Co-Investigator
  
• January 2011–December 2012
  VX-770 Expanded Access Program (EAP).
  Vertex Pharmaceuticals, Inc.
  Role: Co-Investigator
  
• –December 2012
  Remnant Biological and Autopsy Specimens for Cystic Fibrosis Cell Line Development: New Reagents for Understanding and Overcoming the deltaF508 Mutation.
  Cystic Fibrosis Foundation Therapeutics; UAB Center for Clinical and Translational Science
  Role: Co-Investigator
  
• –December 2012
  G551D Observational Study (GOAL) Gastrointestinal pH sub-study.
  Cystic Fibrosis Foundation
  Role: Co-Investigator
  
• January 2010–January 2012
  An Open-Label, Rollover Study to Evaluate the Long-Term Safety and Efficacy of VX-770 in Subjects with Cystic Fibrosis
  Vertex Pharmaceuticals, Inc.
  Role: Co-Investigator
  
• –December 2011
  Nasal Potential Difference (NPD) Measurements Remote Reading Services for Multi-Center Trial Entitled: Nasal Potential Studies Utilizing CFTR Modulators.
  UAB Center for Clinical and Translational Science
  Role: Co-Investigator
  
• January 2014
  A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
  Vertex Pharmaceuticals
  Role: Principal Investigator
  
• February 2012
  G551D Observational Study (GOAL)
  Cystic Fibrosis Foundation
  Role: Principal Investigator
  
• January 2012
  A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors.
  A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients
  Role: Principal Investigator
  
• January 2010
  Microbiology of Cystic Fibrosis Sputum.
  Cystic Fibrosis Foundation
  Role: Co-Investigator
  
• January 2010
  A Phase 2, Multicenter, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of VX-809 Alone and in Combination with VX-770 in Subjects with Cystic Fibrosis, Homozyg
  Vertex Pharmaceuticals
  Role: Co-Investigator